These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 26050991)
1. Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy. Van Ry PM; Wuebbles RD; Key M; Burkin DJ Mol Ther; 2015 Aug; 23(8):1285-1297. PubMed ID: 26050991 [TBL] [Abstract][Full Text] [Related]
2. SU9516 Increases α7β1 Integrin and Ameliorates Disease Progression in the mdx Mouse Model of Duchenne Muscular Dystrophy. Sarathy A; Wuebbles RD; Fontelonga TM; Tarchione AR; Mathews Griner LA; Heredia DJ; Nunes AM; Duan S; Brewer PD; Van Ry T; Hennig GW; Gould TW; Dulcey AE; Wang A; Xu X; Chen CZ; Hu X; Zheng W; Southall N; Ferrer M; Marugan J; Burkin DJ Mol Ther; 2017 Jun; 25(6):1395-1407. PubMed ID: 28391962 [TBL] [Abstract][Full Text] [Related]
4. Protein-Anchoring Therapy of Biglycan for Mdx Mouse Model of Duchenne Muscular Dystrophy. Ito M; Ehara Y; Li J; Inada K; Ohno K Hum Gene Ther; 2017 May; 28(5):428-436. PubMed ID: 27485975 [TBL] [Abstract][Full Text] [Related]
5. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy. D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791 [TBL] [Abstract][Full Text] [Related]
7. Loss of sarcospan exacerbates pathology in mdx mice, but does not affect utrophin amelioration of disease. Gibbs EM; McCourt JL; Shin KM; Hammond KG; Marshall JL; Crosbie RH Hum Mol Genet; 2021 Apr; 30(3-4):149-159. PubMed ID: 33432327 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Miura P; Chakkalakal JV; Boudreault L; Bélanger G; Hébert RL; Renaud JM; Jasmin BJ Hum Mol Genet; 2009 Dec; 18(23):4640-9. PubMed ID: 19744959 [TBL] [Abstract][Full Text] [Related]
9. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963 [TBL] [Abstract][Full Text] [Related]
17. Transgenic overexpression of dystroglycan does not inhibit muscular dystrophy in mdx mice. Hoyte K; Jayasinha V; Xia B; Martin PT Am J Pathol; 2004 Feb; 164(2):711-8. PubMed ID: 14742274 [TBL] [Abstract][Full Text] [Related]
18. Social stress is lethal in the mdx model of Duchenne muscular dystrophy. Razzoli M; Lindsay A; Law ML; Chamberlain CM; Southern WM; Berg M; Osborn J; Engeland WC; Metzger JM; Ervasti JM; Bartolomucci A EBioMedicine; 2020 May; 55():102700. PubMed ID: 32192914 [TBL] [Abstract][Full Text] [Related]
19. Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Rooney JE; Gurpur PB; Burkin DJ Proc Natl Acad Sci U S A; 2009 May; 106(19):7991-6. PubMed ID: 19416897 [TBL] [Abstract][Full Text] [Related]
20. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy. Perkins KJ; Davies KE FEBS Lett; 2018 Jun; 592(11):1856-1869. PubMed ID: 29772070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]